- Home
- EPRX vs RCEL Comparison
EPRX vs RCEL Comparison
Compare EPRX & RCEL Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- EPRX
- RCEL
- Stock Information
- Founded
- EPRX 2011
- RCEL N/A
- Country
- EPRX Canada
- RCEL United States
- Employees
- EPRX N/A
- RCEL N/A
- Industry
- EPRX
- RCEL Medical/Dental Instruments
- Sector
- EPRX
- RCEL Health Care
- Exchange
- EPRX NYSE
- RCEL Nasdaq
- Market Cap
- EPRX 137.7M
- RCEL 161.5M
- IPO Year
- EPRX N/A
- RCEL N/A
- Fundamental
- Price
- EPRX $4.32
- RCEL $5.19
- Analyst Decision
- EPRX Strong Buy
- RCEL Strong Buy
- Analyst Count
- EPRX 1
- RCEL 4
- Target Price
- EPRX $9.00
- RCEL $16.50
- AVG Volume (30 Days)
- EPRX 14.5K
- RCEL 287.8K
- Earning Date
- EPRX 08-07-2025
- RCEL 08-07-2025
- Dividend Yield
- EPRX N/A
- RCEL N/A
- EPS Growth
- EPRX N/A
- RCEL N/A
- EPS
- EPRX N/A
- RCEL N/A
- Revenue
- EPRX N/A
- RCEL $71,661,000.00
- Revenue This Year
- EPRX N/A
- RCEL $57.29
- Revenue Next Year
- EPRX N/A
- RCEL $28.07
- P/E Ratio
- EPRX N/A
- RCEL N/A
- Revenue Growth
- EPRX N/A
- RCEL 41.35
- 52 Week Low
- EPRX $2.20
- RCEL $5.10
- 52 Week High
- EPRX $4.49
- RCEL $14.16
- Technical
- Relative Strength Index (RSI)
- EPRX N/A
- RCEL 29.07
- Support Level
- EPRX N/A
- RCEL $5.10
- Resistance Level
- EPRX N/A
- RCEL $6.33
- Average True Range (ATR)
- EPRX 0.00
- RCEL 0.32
- MACD
- EPRX 0.00
- RCEL 0.02
- Stochastic Oscillator
- EPRX 0.00
- RCEL 6.10
About EPRX EUPRAXIA PHARMACEUTICALS INC
Eupraxia Pharmaceuticals Inc is a clinical-stage biotechnology company focused on the development of locally delivered, extended-release alternatives to existing pharmaceuticals. Its product EP-104 is used for the treatment of osteoarthritis and eosinophilic esophagitis symptoms. The company leverages its proprietary Diffusphere technology to optimize drug delivery for applications with unmet medical needs.
About RCEL Avita Medical Inc.
Avita is a single product company. Its RECELL system is an innovative burn treatment device which creates Spray-on Skin from a small skin sample within 30 minutes, thus avoiding or reducing the need for skin grafts. It's approved for the treatment of adult and paediatric patients in the US and an expanded indication for soft-tissue reconstruction. It is currently in roll-out across the approximately 136 US burn centers. Despite having product approval in Australia, Europe, Canada, and China, Avita is not actively marketing in those territories and focussing instead on the US region. However, it is expected to launch in Japan via distribution partner Cosmotec in second-half fiscal 2022. Avita is domiciled, and has its primary listing, in the US.